Brain cancer trial tests G-CSF to shield thinking skills
NCT ID NCT06649851
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 13 times
Summary
This study tests whether a drug called G-CSF (filgrastim) can help preserve brain structure and thinking abilities in people with a specific type of glioblastoma (MGMT-methylated) who are receiving standard chemotherapy and radiation. About 60 participants will be randomly assigned to receive G-CSF or not, and researchers will measure brain volume changes and cognitive function over a year. The goal is to reduce brain damage from cancer treatment, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MGMT-METHYLATED GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.